Using a longitudinal case-control study, O’Bryant et al. (2010) found that serum protein-based biomarkers involving IGFBP-2 protein can be combined with clinical information to accurately classify AD (O’Bryant et al., 2010). This evidence concerns the gene IGFBP2 and Alzheimer disease.